Vimian Group AB (publ)
VIMGF
Other OTC2.77
USD
- -
- -
ISIN
SE0015961982
Return %
Stock
S&P500
1Y
-35.58
18.21
3Y
-16.57
63.29
5Y
-23.69
74.90
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alireza Tajbakhsh
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- Riddargatan 19 Stockholm AB Sweden 11457
- IPO Date
- Aug 22, 2022
- Website
- vimian.com
- Similar Companies
- Business
- Vimian Group AB (publ) is a global animal health company focused on specialty pharmaceuticals, medical technology, veterinary services and diagnostics for companion animals. Headquartered in Stockholm, Sweden, and founded in 2015, the company operates through key brands including Nextmune in specialty pharma; Movora in medtech; VetFamily in veterinary services; and Indical Bioscience in diagnostics, offering proprietary diagnostics, prescription and non-prescription treatments for preventive care and chronic conditions such as allergy, dermatology, specialised nutrition and specialty pharmaceuticals; orthopedic implants, power tools, instruments, sutures and adjunct products comprising approximately 6,000 items; veterinary clinic management platforms and services; and laboratory diagnostics reaching over 17,000 veterinary clinics and 1,700 labs across more than 80 markets with around 1,200 employees and annual revenues of approximately EUR 375 million. Vimian targets veterinarians, laboratories and pet owners worldwide, delivering innovative solutions through forward-leaning R&D, global distribution and professional training. In recent developments, Vimian acquired AllAccem Inc. in June 2025 to expand its veterinary dental sealant offerings; IMEX Veterinary Inc. in August 2025 to strengthen orthopedic implants and external fixation; iM3 Dental Limited and iM3 Pty Ltd in September 2024 for veterinary dental products and equipment; and product portfolios of veterinary surgical instruments and orthopedic implants, alongside appointing Alireza Tajbakhsh as CEO effective November 2025 and adopting new financial targets emphasizing double-digit organic growth, margin expansion and value-creative acquisitions following 32 deals that doubled revenues.
Vimian Group AB (publ) (VIMGF) Q2 2026 Earnings Call Transcript
Vimian Group AB (publ) (VIMGF) Q1 2026 Earnings Call Transcript
Vimian Group AB (publ) (VIMGF) Q4 2025 Earnings Call Transcript